| Basics |
Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
|
| IPO Date: |
November 11, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$963.34M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.48 | 3.34%
|
| Avg Daily Range (30 D): |
$0.20 | 2.95%
|
| Avg Daily Range (90 D): |
$0.31 | 3.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
1.26M |
| Avg Daily Volume (90 D): |
1.1M |
| Trade Size |
| Avg Trade Size (Sh.): |
107 |
| Avg Trade Size (Sh.) (30 D): |
87 |
| Avg Trade Size (Sh.) (90 D): |
78 |
| Institutional Trades |
| Total Inst.Trades: |
988 |
| Avg Inst. Trade: |
$1.43M |
| Avg Inst. Trade (30 D): |
$1.11M |
| Avg Inst. Trade (90 D): |
$1.34M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$1.16M |
| Avg Closing Trade (90 D): |
$1.44M |
| Avg Closing Volume: |
170.03K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.74
|
$-.29
|
$.27
|
|
Diluted EPS
|
$-.74
|
$-.29
|
$.27
|
|
Revenue
|
$ 104.94M
|
$ 9.18M
|
$ 83.75M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -112.33M
|
$ -46.88M
|
$ 29.25M
|
|
Operating Income / Loss
|
$ -125.75M
|
$ -49.8M
|
$ 22.97M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 62.22M
|
$ -59.05M
|
$ -8.75M
|
|
PE Ratio
|
|
|
|
|
|
|
